FY2025 · ended Dec 31, 2025 · Revenue $14,825, -57.5% YoY · Filed Mar 13, 2026
Cardio Diagnostics Holdings, Inc. (CDIO) files with the SEC under industry code 2835, In Vitro & In Vivo Diagnostic Substances. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $14,825 and a net loss of $6.5 million. Free cash flow was -$5.9 million. As of Jun 30, 2026 it held $0 in cash and investments and $302,250 in total debt.
Revenue (TTM)
$14,450
-25.9% vs year-ago TTM
Net income (TTM)
$-6.47M
-3.5% vs year-ago TTM
Operating cash flow (TTM)
$-5.66M
-2.5% vs year-ago TTM
Free cash flow (TTM)
$-5.82M
-4.5% vs year-ago TTM
EPS (TTM)
$-2.77
+38.8% vs year-ago TTM
Dividend per share
None
Shares outstanding
2.96M
-94.3% vs prior year
Net cash
$-302,250
as of Jun 30, 2026
Operating margin
-44690.7%
FY 2026
Company profile
- Industry
- In Vitro & In Vivo Diagnostic Substances (SIC 2835)
- Listed as
- CDIO (Nasdaq), CDIOW (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Chicago, IL
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1870144
- Former names
- Mana Capital Acquisition Corp. (until Oct 26, 2022)
Other In Vitro & In Vivo Diagnostic Substances companies
- Idexx Laboratories Inc /DE IDXX
- Lantheus Holdings, Inc. LNTH
- Neogen Corp NEOG
- Celldex Therapeutics, Inc. CLDX
- Intellia Therapeutics, Inc. NTLA
- QuidelOrtho Corp QDEL
- Achieve Life Sciences, Inc. ACHV
- Myriad Genetics Inc MYGN
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
|---|---|---|---|---|
| Revenue | $14,825 | $34,890 | $17,065 | $950 |
| Operating income | -$6.5M | -$8.4M | -$7.2M | -$4.5M |
| Net income | -$6.5M | -$8.4M | -$8.4M | -$4.7M |
| Diluted EPS | -$3.71 | -$9.35 | -$0.66 | -$1.51 |
| Operating cash flow | -$5.7M | -$5.0M | -$5.7M | -$5.1M |
| Free cash flow | -$5.9M | -$5.2M | -$6.2M | — |
| Total assets | $7.8M | $10.6M | $4.5M | $6.2M |
| Total liabilities | $793,061 | $1.1M | $1.5M | $1.9M |
| Stockholders' equity | $7.0M | $9.6M | $3.0M | $4.3M |
| Cash and investments | $0 | $0 | — | $0 |
| Total debt | $425,829 | $425,829 | $642,523 | — |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Shareholder vote results
|
Sep 18, 2026 | Sep 18, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Aug 20, 2026 | Aug 20, 2026 |
| 10-Q | Quarterly report | Aug 7, 2026 | Jun 30, 2026 |
| ARS | Annual report to shareholders | Jul 23, 2026 | Dec 31, 2025 |
| 10-Q | Quarterly report | May 15, 2026 | Mar 31, 2026 |
| 10-K | Annual report | Mar 13, 2026 | Dec 31, 2025 |
All 295 Cardio Diagnostics Holdings, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.